YLYan Liu

Yan Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yan Liu has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Dongping Xu

    Research Center for Clinical and Translational Medicine, Beijing 302 Hospital, Beijing, China

    3 shared publications
  • Feilin Ge

    Department of Chinese Medicine, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

    3 shared publications
  • Le Li

    Senior Department of Infectious Diseases Chinese PLA General Hospital Beijing China

    3 shared publications
  • Dong Ji

    Senior Department of Hepatology Chinese PLA General Hospital Beijing China

    2 shared publications
  • Hao Liao

    Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China

    2 shared publications
  • Jun Wang

    Senior Department of Infectious Diseases, the Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China

    2 shared publications

Latest Publications

  • Open Access

    Metabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large‐Scale, Multicenter Study

    by Yongjie Xu, Jiachen Wang, Chunmeng Ding, Changfa Xia, Yunyong Liu, Yuanjie Zheng, Sheng Chang, Shaokai Zhang, Yutong He, Ruifang Sun, et al.

    The poor prognosis of liver cancer (LC) highlights the urgent need for more effective strategies for early detection. We conducted a large, multicenter study to develop and validate a serum metabolic signature for LC diagnosis. Using high‐throughput nanoparticle‐enhanced laser desorption/ionization mass spectrometry, we profiled serum metabolites from 1,924 participants in discovery cohort recruited across 11 clinical centers and 225 participants in independent external validation cohort from two additional centers. A nine‐metabolite signature combined with alpha‐fetoprotein achieved excellent discriminatory performance, with an AUC of 0.92 in the discovery cohort and 0.93 in the external validation cohort. The combined model also showed good sensitivity for early‐stage LC, reaching 0.85 and 0.78 in the two cohorts, respectively, and performed particularly well for hepatocellular carcinoma, with AUCs of 0.94 and 0.93. Exploratory analyses suggested potential utility for intrahepatic cholangiocarcinoma diagnosis. Mendelian randomization analysis supported a potential causal association between nicotinamide (NAM) levels and LC risk. Functional studies showed that NAM promotes LC cell proliferation, migration, and invasion, through an NAD + /SIRT1‐dependent mechanism that increases HIF1α stability and activates glycolytic and MAPK signaling. Overall, we developed a promising metabolic diagnostic signature for LC and identified NAM‐associated metabolic signaling as a potential contributor to LC progression.

  • Open Access

    Direct viral invasion and tumor-like pulmonary nodules: A fatal case of mpox in a patient with advanced HIV disease

    by Sen Yang, Qing Yu, Yanming Zeng, Yanqiu Lu, Chao Xia, Fang Cheng, Yan Liu, Min Liu, Yemiao Chen

  • HBsAg Quantification‐Based Models for Predicting Hepatocellular Carcinoma Risk in Nucleos(t)ide Analogs‐Experienced Patients With Chronic Hepatitis B: The HBsAg ‐ HCC Score

    by Yi‐Fan Guo, Xiao‐Xia Niu, Le Li, Yan Chen, Yan Liu, Chang Guo, Meng‐Qi Sun, Yi‐Zhe Zhang, Xu‐Yang Li, Chun‐Yan Wang, et al.

    Background: Chronic hepatitis B (CHB) virus infection is the leading cause of hepatocellular carcinoma (HCC). Nucleos(t)ide analogs (NAs) effectively suppress HBV replication, but residual HCC risk remains in treated patients, highlighting the need for reliable risk stratification tools. Existing prediction models rely heavily on age and liver function parameters and often overlook hepatitis B surface antigen (HBsAg) quantification, a key marker closely tied to HBV‐related HCC, resulting in inadequate clinical predictive accuracy. Methods: To address this gap, we developed the novel HBsAg‐HCC Score using a two‐cohort design: retrospective training (1190 NA‐treated CHB patients) with Cox regression to identify independent HCC risk factors, followed by validation in an independent prospective cohort (506 patients). Its performance was compared with three established tools (PAGE‐B, mPAGE‐B, aMAP). Results: Five independent HCC risk factors were identified: higher HBsAg levels, older age, male sex, hypoproteinaemia, and elevated APRI. The HBsAg‐HCC Score derived from these factors showed strong predictive power: 3‐/5‐/7‐year AUCs of 0.867/0.872/0.871 in the training cohort (significantly outperforming PAGE‐B, mPAGE‐B, aMAP) and 0.784/0.780/0.777 in the validation cohort. Internal and external cross‐validation confirmed its stability and reliability. Conclusions: By incorporating HBsAg quantification, a virus‐specific marker often missing from conventional models, the HBsAg‐HCC Score offers a more comprehensive and accurate approach to HCC risk stratification in NAs‐experienced CHB patients, addressing a critical limitation of existing models directly.


  • Open Access

    Hepatitis B virus rtCYE/rtCYEI mutations may contribute limited tenofovir resistance: Analysis of a large sample of Chinese patients

    by Lan-Lan Si, Zhen-Ping Fan, Wen-Hui Liu, Rong-Juan Chen, Xue-Yuan Chen, Dong Ji, Le Li, Chun Chen, Hao Liao, Jun Wang, et al.

    BACKGROUND Whether rtS106C+H126Y+D134E/rtS106C+H126Y+D134E+L269I (rtCYE/rtCYEI) mutations in the hepatitis B virus (HBV) reverse-transcriptase (RT) region are associated with tenofovir disoproxil fumarate (TDF) resistance is controversial. AIM To evaluate the presence of the rtCYE/rtCYEI mutations in a large cohort of Chinese patients with chronic HBV infection. METHODS A total of 28236 patients who underwent drug resistance testing at the Fifth Medical Center of Chinese PLA General Hospital from 2007 to 2019 were enrolled. All patients received nucleoside/nucleotide analogues (NAs) therapy, and serum samples were collected for sequence analysis of the HBV RT domain with mutation analysis. RESULTS The detection rates of a single mutation of rtS106C, rtH126Y, rtD134E, and rtL269I were 8.21%, 3.20%, 2.55% and 61.49% in 23718 genotype C patients, and 1.31%, 1.76%, 0.21%, and 92.33% in 4266 genotype B patients, respectively. The combined mutations of rtCYE/rtCYEI were only detected in 12 genotype C patients, accounting for 0.042% of all patients. These 12 patients had received NA treatments except TDF before testing. Among them, 6 patients had coexisting rtCYE/rtCYEI and lamivudine-resistance mutations, and 2 patients had coexisting rtCYE/rtCYEI and adefovir-resistance mutations. Compared with the wild-type (WT) strain, the replication capacity of rtCYE/rtCYEI mutants from representative patients decreased by 41.1%-71.8%, and TDF susceptibility reduced by less than 2-fold, but rtCYEI+rtA181V/N236T mutants exhibited a 6.2-/9.9-fold decrease in TDF susceptibility. Molecular modeling showed that rtCYE/rtCYEI mutants had a slight decrease in binding energy to TDF compared to the WT strain. In the clinic, emergence of the rtCYE/rtCYEI mutations was not specifically associated with TDF treatment. CONCLUSION HBV rtCYE/rtCYEI mutations have a limited effect on TDF susceptibility and are not sufficient to cause TDF resistance.

  • Open Access

    Inhibition of hepatitis B virus via selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet

    by Fei-Lin Ge, Yan Yang, Lan-Lan Si, Yuan-Hua Li, Meng-Zhen Cao, Jun Wang, Zhao-Fang Bai, Zhi-Gang Ren, Xiao-He Xiao, Yan Liu

    Inhibition of hepatitis B virus via selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet


  • Open Access

    PreS1BP mediates inhibition of Hepatitis B virus replication by promoting HBx protein degradation

    by Jun Wang, Xiaoxue Yuan, Yun Wang, Yu Zhang, Ming Han, Hongping Lu, Shunai Liu, Yang Zhang, Feilin Ge, Yan Liu, et al.


  • Open Access

    The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges

    by Feilin Ge, Yan Yang, Zhaofang Bai, Lanlan Si, Xuemei Wang, Jia Yu, Xiaohe Xiao, Yan Liu, Zhigang Ren

    Chronic hepatitis B (CHB) remains a major world's most serious public health issues. Despite the remarkable effect of nucleos(t)ide analogues (NAs) in inhibiting hepatitis B virus (HBV) deoxyribonucleic acid (DNA) as the first-line drug, there are several limitations still, such as poor antigen inhibition, drug resistance, low-level viremia, restricting patients' functional cure. Due to the constraints of NAs, traditional medicines, such as traditional Chinese medicine (TCM), have become more prevalently used and researched in the clinical treatment of CHB as complementary alternative therapies. As a consequence, the review focuses on the background based on HBV’s life cycle as well as the NAs’ limitations, progress based on direct and indirect pathway of targeting HBV of TCM, and challenges of TCM. We found TCMs play an increasingly important role in anti-HBV. In a direct antiviral way, they regulate HBV infection, replication, assembly, and other aspects of the HBV life cycle. As for indirect way, TCMs can exert anti-HBV effects through targeting the host, including immune regulation, apoptosis, autophagy, oxidative stress, etc. Especially, TCMs have the advantages of strong antigenic inhibition compared to NAs. Specifically, we can combine the benefits of TCMs in strong HBV antigen inhibition with the benefits of NAs in targeted antiviral effects, in order to find a suitable combination of "TCM + NAs" to contribute to Chinese knowledge of the realisation of the “global elimination of HBV by 2030” goal of the World Health Organization.


  • Open Access

    Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients

    by Hao Liao, Le Li, Wei V. Zheng, Jun Zou, Guangxin Yu, Lanlan Si, Feilin Ge, Tao Zhou, Dong Ji, Xiangmei Chen, et al.

    Background and aims. To investigate the clinical implications of serum HBV RNA, serum hepatitis B core-related antigen (HBcrAg), and quantitative anti-HBc in treatment-naïve patients with chronic HBV infection. Methods. A total of 111 patients in total from different disease phases were recruited, including 21 in immune-tolerant (IT) phase, 49 in immune-clearance (IC) phases, 29 in immune-control or low replicative (LR) phase, and 12 in reactivation phases. Serum HBV RNA, anti-HBc, HBcrAg, and intrahepatic covalently closed circular DNA (cccDNA) were quantified and each of these indicator’s correlation with liver inflammation was analyzed. Results. HBeAg-positive individuals had significant higher serum levels of HBV RNA and HBcrAg than those who were HBeAg negative, similar to that of serum HBV DNA. Comparatively, HBV RNA ( =0.79, ) and HBcrAg ( =0.78, ) had almost same higher overall correlation with the cccDNA, as that of HBV DNA ( =0.81, ). Serum anti-HBc level ( = -0.52, ) is negatively correlated with cccDNA level at IT phase rather than the other three phases. When set the cutoff value at 4.00 log10 IU/mL, serum anti-HBc showed potential to indicate liver inflammation, with AUC as 0.79 and the specificities as 78.85% for HBeAg positive, and with AUC as 0.72 and the specificities as 62.16% for HBeAg-negative patients, respectively. Conclusions. In treatment-naïve patients, levels of serological markers HBV RNA and HBcrAg could mirror intrahepatic cccDNA level, but were not superior to HBV DNA level. Serum anti-HBc level had certain potential to be used as a predicting marker for liver inflammation.


  • Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation

    by Li Zhao, Xiaodong Li, Yongqian Cheng, Rongjuan Chen, Jinman Shao, Yi Zhou, Qi Li, Hao Liao, Yangyang Zhao, Lujie Liu, et al.


  • Risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis

    by Zilin Tang, Xiaodong Li, Shunquan Wu, Yan Liu, Yan Qiao, Dongping Xu, Jin Li

    Background Hepatitis B surface antigen (HBsAg)-negative/hepatitis B core antibody (HBcAb)-positive patients with undetectable serum hepatitis B virus (HBV) DNA have experienced and resolved hepatitis B virus (HBV) infection. Lymphoma patients with resolved HBV infection have high risk of HBV reactivation when treated with robust immunosuppressive agents, but the reported rate varies extensively between different studies. This study aims to estimate the risk of HBV reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab-containing chemotherapy for lymphoma. Methods Databases were searched for papers published in English until 8 August 2016. The pooled risk of HBV reactivation was estimated using a random-effects model. Results Data from 15 studies were retrieved, including a total of 1312 HBsAg-negative/HBcAb-positive lymphoma patients treated with rituximab-containing chemotherapy. The results revealed HBV reactivation rate of 9.0 % [95 % confidence interval (CI) 0.05–0.15]. In subgroup analysis, the reactivation rates for prospective and retrospective studies were 17 % (I 2 = 87.3 %; 95 % 0.08–0.39, p < 0.001) and 7 % (I 2 = 43.1 %; 95 % CI 0.05–0.11, p = 0.07), respectively. Conclusions This meta-analysis confirms a measurable and potentially substantial risk of HBV reactivation in HBsAg-negative/HBcAb-positive patients with rituximab treatment for lymphoma. Prophylactic use of anti-HBV agents should be seriously considered for such patients.